<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区

          Science and Health

          Drugmakers cut vaccine prices for poorer nations

          (Agencies)
          Updated: 2011-06-06 23:07
          Large Medium Small

          LONDON - Several leading drugmakers are cutting their prices on potentially life-saving vaccines for people in developing countries in an effort to sustain supplies via the GAVI international vaccine alliance.

          The price cuts, offered by both generic and branded drugmakers including GlaxoSmithKline, Merck, Johnson & Johnson's Crucell and Sanofi-Aventis' Sanofi Pasteur, should help the alliance narrow a $3.7 billion funding gap for its commitments up until 2015.

          GSK said on Monday it would provide its Rotarix rotavirus vaccine to GAVI at a 67 percent discount to the current public price -- bringing it to $2.50 per dose, or $5 to fully immunise a child.

          Merck said it will offer its Rotateq rotavirus shot at $5.00 a dose initially. "The RotaTeq price will decrease to $3.50 once the purchase volume increases to 30 million doses," it said.

          Julie Gerberding, president of Merck Vaccines said long-term purchase commitments help to speed up availability of vaccines.

          "Confirming volumes to be purchased will enable further price reductions as manufacturers expand production and lower costs in the future allowing for greater access," she added.

          Diarrhoea is one of the top two killers of children under five worldwide and rotavirus is the leading cause of severe diarrhoeal disease in children. Each year, rotavirus-related diarrhoea kills more than 500,000 children.

          In 2009, the WHO recommended that all countries should include rotavirus vaccines in national vaccination programmes, but many poorer countries struggle to afford them.

          GAVI, which funds bulk-buy vaccination programmes for nations that can't afford shots at Western prices, has committed to help fund rotavirus vaccine introduction in at least 40 of the world's poorest countries by 2015.

          But the alliance is facing a shortfall of $3.7 billion to fund it projects through to 2015, and has been seeking extra donor money and price cuts from drug firms to close that gap. It has a pledging conference in London on June 13.

          "These are promising offers that demonstrate industry commitment to work towards affordable and sustainable prices," Helen Evans, GAVI's interim chief executive, said in a statement.

          GSK said it had offered to supply up to 125 million doses of Rotarix over five years at an approximately 95 percent price cut from the Western market price.

          "Whilst most babies in the world will get rotavirus at some point, those in developing countries do not have access to the medical care they need which means millions of babies die unnecessarily," GSK's CEO Andrew Witty said in a statement.

          He said the British drugmaker was committed to finding new ways to get urgently needed vaccines to children in poor countries.

          Evans said that if rotavirus vaccine could be purchased this year at $2.50 a dose, the impact on public health could be significant and would allow GAVI to save approximately $500 million through to 2020, or about $140 million through to 2015.

          The price GAVI pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, will also be cut by the India-based firms Serum Institute and Panacea Biotec.

          Serum, which had already cut its price to $1.75 a dose, said it would "continue to provide the most competitive pricing," while Panacea said it would cut its price by up to 15 percent.

          Crucell and Sanofi Pasteur said they would extend GAVI prices on their pentavalent vaccines to 16 countries who are moving on from GAVI support to begin buying shots themselves.

          Sanofi Pasteur said this would also apply to its yellow fever vaccine and a rotavirus vaccine being developed by its Indian subsidiary Shantha.

          Merck also announced it will offer GAVI its Gardasil shot, which protects the human papillomavirus (HPV) that causes cervical cancer, at a discounted price of $5 per dose -- a 67 percent reduction on the current public price.

          Although GAVI has not yet committed to funding HPV vaccines, it said they were part of its investment strategy and it hoped "to see further price reductions." More than 90 percent of deaths from cervical cancer now occur in developing countries, killing 200,000 women a year.

          分享按鈕
          主站蜘蛛池模板: 国产精品亚洲片夜色在线| 国产精品揄拍一区二区久久| 成人精品一区日本无码网| 四虎库影成人在线播放| 97精品亚成在人线免视频 | 久久亚洲精品人成综合网| 色欲综合久久中文字幕网| 国产成人99亚洲综合精品| 欧洲精品一区二区三区久久 | 女同AV在线播放| 亚洲人亚洲人成电影网站色| 试看120秒做受| 国产精品亚洲中文字幕| 国产高潮大叫在线观看| 日韩人妻不卡一区二区三区| 成人国产精品日本在线观看| 免费观看全黄做爰大片| 国产亚洲视频免费播放| 亚洲色欲在线播放一区二区三区| 亚洲 日本 欧洲 欧美 视频| 亚洲女同精品一区二区久久| 中文字幕亚洲人妻系列| 性夜久久一区国产9人妻| 国产精品成人一区二区三区| 国产成人女人在线观看| 香蕉乱码成人久久天堂爱| 国产精品99久久免费| 中文字幕在线无码一区二区三区 | 国产欧美日韩专区发布| 久久国产免费观看精品3| 欧美性一区| 久久中文字幕一区二区| 亚洲AV无码精品色欲av| 国产精品福利自产拍久久| 久久婷婷五月综合97色一本一本| 国产一区二区三区不卡自拍| 久久一日本道色综合久久| 日本九州不卡久久精品一区| 中国亚州女人69内射少妇| 亚洲无人区码二码三码区| 亚洲熟妇少妇任你躁在线观看无码|